除业绩预期下调外，诺和诺德还宣布了重要的管理层变动。现任CEO Lars Fruergaard Jørgensen将于8月7日卸任，由国际运营经验丰富的Maziar Mike Doustdar接任。这一变动引发了投资者对公司未来战略方向的担忧。此外，公司还面临着GLP-1配方药品持续使用的挑战，这些非正规渠道的产品正在蚕食其市场份额。面对这些挑战，市场正密切关注诺和诺德能否通过新的管理团队、创新研发和市场策略来扭转局面，重新赢得投资者的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.